Handelsbanken Fonder Ab Novavax Inc Transaction History

Handelsbanken Fonder Ab

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	BUY	$8.86 - $25.04 $114,293 - $323,016	12,900 Added 105.74%	25,100 $258,000
Q2 2022 Aug 03, 2022	BUY	$36.28 - $75.29 $50,792 - $105,406	1,400 Added 12.96%	12,200 $627,000
Q1 2022 May 11, 2022	SELL	$69.73 - $142.9 $104,595 - $214,350	-1,500 Reduced 12.2%	10,800 $795,000
Q4 2021 Feb 08, 2022	SELL	$134.56 - $217.97 $67,280 - $108,985	-500 Reduced 3.91%	12,300 $1.76 Million
Q3 2021 Nov 10, 2021	BUY	$177.8 - $270.58 $106,680 - $162,348	600 Added 4.92%	12,800 $2.65 Million
Q2 2021 Aug 03, 2021	BUY	$121.0 - $257.67 $108,900 - $231,903	900 Added 7.96%	12,200 $2.59 Million
Q4 2020 Feb 11, 2021	BUY	$78.74 - $139.5 $889,762 - $1.58 Million	11,300 New	11,300 $1.26 Million

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $662M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.